Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

August 29, 2025

Study Completion Date

March 31, 2026

Conditions
Mycobacterium Avium Complex
Interventions
DRUG

Clofazimine

All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.

OTHER

sugar pill

All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.

Trial Locations (7)

20814

National Heart, Lung and Blood Institute, Bethesda

33620

University of South Florida, Tampa

60637

University of Chicago, Chicago

70803

Louisiana State University, Baton Rouge

75708

University of Texas Health Science Center, Tyler

80206

National Jewish Health, Denver

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Jewish Health

OTHER

collaborator

The University of Texas Health Science Center at Tyler

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of Chicago

OTHER

collaborator

Temple University

OTHER

collaborator

University of South Florida

OTHER

lead

Oregon Health and Science University

OTHER